Morning Briefing
Summaries of health policy coverage from major news organizations
Research Roundup: Diabetes; Paxlovid; MIS-C; Healthy Air On Cruise Ships
A new聽study presents exciting future possibilities for the management of type 1 diabetes and the potential reduction of insulin dependency. The study's findings聽suggest repurposing of the drug alpha-difluoromethylornithine (DFMO) may open doors to innovative therapies in the future. (Indiana University, 11/1)
A study based on 211 pregnant women given the antiviral drug nirmatrelvir and ritonavir (Paxlovid) during pregnancy for acute COVID-19 infections shows no increased risk of adverse events in the women or their babies and a reduced risk of complications called the maternal morbidity and mortality index (MMMI). (Soucheray, 11/1)
A pair of studies sheds new light on the SARS-CoV-2鈥搑elated multisystem inflammatory syndrome in children (MIS-C), with Dutch researchers finding that previous COVID-19 infection helps protect children against the condition, and a US study showing that low-dose corticosteroids and intravenous immunoglobulin (IVIG) were tied to shorter hospital stays and less severe disease. Both studies were published in the Pediatric Infectious Disease Journal. (Van Beusekom, 11/1)
A simulation looking at coughing and droplet spread in cruise ship passenger cabins meant for two or more passengers shows that higher ventilation does not necessarily lead to the best viral protection. The study is published in Physics of Fluids. (Soucheray, 11/1)
